Statement from the Alzheimer's Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder
The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape
NEW YORK, June 15, 2025 /PRNewswire/ -- It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard A. Lauder. A visionary philanthropist, cosmetics industry icon, and steadfast champion in the fight against Alzheimer's disease, Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's.
"Leonard Lauder was a once-in-a-generation visionary whose leadership, along with his brother Ronald, reshaped the Alzheimer's research landscape," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "From the very beginning, Leonard understood that Alzheimer's does not just impact the patient, it affects entire families. The Lauder family recognized the emotional, financial, and societal toll of this disease, and built the ADDF to accelerate the discovery and development of treatments that could change the trajectory for patients and their loved ones. Leonard's vision, generosity, and humanity spanned across his business acumen to his philanthropic endeavors, touching countless lives, and his legacy will endure in every breakthrough we help bring forward."
Lauder and his brother, Ronald S. Lauder, co-founded the ADDF in 1998 with Dr. Fillit in honor of their mother, Estee Lauder's, battle with Alzheimer's. At a time when Alzheimer's research funding was sparse and interest from the private sector limited, the Lauder family recognized the urgent need for treatments and created a bold new venture philanthropy model to achieve this mission, combining the rigor of scientific research with the agility and entrepreneurialism of venture capital.
For over more than 27 years, the Lauders' leadership helped shape the ADDF into the world's leading philanthropic funder of drug discovery and development research. Under the Lauders' guidance, the ADDF has:
Invested more than $370 million into over 765 drug discovery programs across 21 countries
Catalyzed more than $3 billion in follow-on funding from pharmaceutical companies, venture capital firms, and government agencies, helping to de-risk early-stage science and attract broader investment into Alzheimer's research
Played a pivotal role in the development of the first biomarkers for Alzheimer's by providing early seed funding for Amyvid, the first FDA-approved PET scan for Alzheimer's; PrecivityAD, the first Alzheimer's blood test to market; and Lumipulse, the first Alzheimer's blood test to receive FDA approval
Established the Diagnostics Accelerator (DxA) in partnership with Bill Gates and other visionary philanthropists to advance affordable, accessible diagnostic tools, a critical step toward earlier detection and intervention
Advanced a diverse pipeline of treatments by pioneering the biology of aging approach, now central to the field, with over 70% of drugs targeting disease pathways such as inflammation, neuroprotection, vascular health, and synaptic function, paving the way for Alzheimer's to be treated with combination therapy and precision medicine, as in cancer
Brought forward a precision prevention approach, combining lifestyle interventions and therapeutics to slow the progression or prevent the onset of Alzheimer's altogether
Through all these achievements, Lauder and his family remained deeply committed to the ADDF's mission.
"Leonard's impact on the ADDF, and on the field of Alzheimer's research more broadly, is immeasurable," said Mark Roithmayr, Chief Executive Officer of the ADDF. "He brought a sense of urgency to this work that pushed us all to do more and move faster. He believed that patients and families deserve better and he committed himself fully to building a world in which effective treatments are not only possible, but inevitable. His leadership, his generosity, and his humanity will continue to guide the ADDF's mission every day."
Lauder's impact extended across business, culture, and philanthropy. Yet for those who worked alongside him at the ADDF, he will be remembered most for his compassion, clarity of purpose, and unwavering belief in progress. He understood that Alzheimer's is a deeply human and societal challenge, one affecting memory, identity, and dignity.
The ADDF honors Lauder's legacy by reaffirming our commitment to conquer Alzheimer's for the millions of patients and families living with this devastating disease.
About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/statement-from-the-alzheimers-drug-discovery-foundation-on-the-passing-of-addf-co-founder-and-co-chairman-leonard-a-lauder-302481866.html
SOURCE Alzheimer's Drug Discovery Foundation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
24 minutes ago
- Medscape
Missed Target Treatment Times May Increase MI Mortality
When it comes to delivering timely treatment for patients experiencing myocardial infarction (MI), many hospitals are continuing to fall short of national guidelines, new research showed. Benchmarks for percutaneous coronary intervention, the standard of care for acute ST-elevation MI (STEMI), aren't being met in some cases. Delays in care in the key metric of the time from first contact with medical care to angioplasty with stenting resulted in worse patient outcomes and were associated with increased in-hospital mortality risk in some cases, according to the findings, published on June 11 in JAMA Cardiology . 'There are two categories of patient delays: Those that are patient-centered and those that are system-centered,' said Neal S. Kleiman, MD, Houston Methodist DeBakey Heart and Vascular Center, Houston, the senior author of the new study. 'We don't have control over patient-related factors, but there is a lot we can do in terms of hospital systems.' For the retrospective cross-sectional study, Kleiman and his colleagues analyzed data on 73,826 patients with STEMI or STEMI equivalent from 503 sites across the United States. The goal was to determine site-level variability in patterns of treatment times and clinical outcomes from 2020 to 2022 based on an analysis of data from the American Heart Association's Get With the Guidelines — Coronary Artery Disease registry — a quality improvement program for patients with coronary artery disease, acute MI and chest pain. The authors said the study is the first large-scale analysis of treatment goals and outcomes in STEMI based on hospital performance. The researchers found an association between failure to reach the target time from first medical contact with care to angioplasty with stenting — 90 minutes or less — and increased risk for in-hospital mortality for primary presentations and transfers (adjusted odds ratio, 2.21; 95% CI, 2.02-2.42, and 2.44; 95% CI, 1.90-3.12, respectively). Low-performing hospitals were associated with increased risk for mortality and longer stays in the hospital than were high-performing hospitals. However, hospital location and case volume were not associated with worse outcomes. The guidelines recommend a target time from first contact with care to angioplasty with stenting of 90 minutes or less for patients presenting directly to hospitals offering angioplasty with stenting and 120 minutes or less for patients requiring transfer to a facility offering the procedure. The study findings revealed significant variability between hospital sites in meeting the key metric of the recommendations — adherence in at least 75% of patients with STEMI. At hospitals with the capability to perform angioplasty with stenting, the target was met in 72.2% of patients at high-performing sites, 60.8% at intermediate-performing sites, and 46.0% at low-performing sites. When patients required transfers to other facilities with the capability to perform angioplasty, a target first medical contact-to-device treatment time of 120 minutes or less was achieved in 72.3% of patients at high-performing sites, 48.8% at intermediate performing sites, and 21.9% at low-performing sites, according to the researchers. In these hospitals, treatment delays were caused primarily by longer stays in the emergency department and time from arrival in the catheterization laboratory to stenting. Limitations of the study included the fact registry responses were provided on a voluntary basis and may not reflect the totality of STEMI care in all geographical areas, according to the researchers. The analysis also lacked data on follow-up after discharge, making it difficult to extrapolate the findings over the long term, they said. Yasser M. Sammour, MD, MSc, cardiology fellow at Houston Methodist DeBakey Heart and Vascular Center, who led the work, said several decades of research have highlighted the importance of treating patients with STEMI efficiently. A previous registry study found fewer treatment delays were linked to reduced mortality. 'The current study tried to take that research one step further, assessing how factors such as hospital performance and location affect patient outcomes,' Sammour said. The result, he said: 'We're still underperforming. We need to have coordinated strategies with local intervention at the hospital level to examine where significant delays in percutaneous coronary intervention time are occurring.' The absence of uniformity in established performance measures such as time to initiate treatment in STEMI has led to calls for greater adherence to current recommendations. In an editorial accompanying the journal article, Roxana Mehran, MD, Mount Sinai Fuster Heart Hospital in New York City, wrote: 'After two decades of data collection, national initiatives, and public accountability, the next step must involve tailored solutions addressing barriers within each institution. Bridging the gap now requires renewed efforts and commitments to prioritize timely, coordinated STEMI care. Until then, the clock will continue to tick — against our patients.'
Yahoo
29 minutes ago
- Yahoo
Can start-up success be taught?
On paper, tech entrepreneur Evan Moore seems a good advertisement for business degrees. While at Stanford's Graduate School of Business, he Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30 minutes ago
- Yahoo
Australia's Albanese says he will press AUKUS, Indo Pacific security in Trump meeting
By Kirsty Needham SYDNEY (Reuters) -Increasing the number of nuclear powered submarines operated by Australia, Britain and the United States will make the Indo Pacific more secure and was in the United States' interests, Australian Prime Minister Anthony Albanese said on Monday. Albanese will meet U.S. President Donald Trump for the first time on Tuesday in Calgary on the sidelines of the G7 meeting, with tariffs and Washington's snap review of the AUKUS treaty to transfer nuclear submarines to Australia weighing on the talks. "Having Australia, the United Kingdom and the United States all having increased nuclear-powered submarines, in our case conventionally armed, is something that will make the Indo Pacific area more secure," Albanese told reporters in Calgary. "That is in the interests of the United States," he added. Albanese said he will highlight to Trump the financial support Australia is providing to the U.S. industrial capacity to build new submarines under AUKUS, the access the U.S. submarine fleet will gain to maintenance yards in Australia, and the existing U.S. military presence in Australia's northern city of Darwin. Australia was a trusted U.S. partner in the Pacific region to promote peace and security, he said. Albanese has rebuffed a U.S. request to commit to lifting defence spending from 2% to 3.5% of gross domestic product, saying instead Australia would spend what was needed for its defence capability. Around 10% of Australia's steel and aluminium is exported to the United States, and Albanese said he would also raise the issue of Trump's tariffs on the sector, which Australia views as "acts of economic self harm". "Exports are still going in there, they are just paying more for them," he told reporters. Albanese met with Canada's Prime Minister Mark Carney on Monday, and said they had discussed Canada's interest in joining AUKUS's so-called Pillar Two to develop advanced defence technology. Australia wants to increase its defence relationships, including with Canada which was a long-term ally with shared values, Albanese said. "In an uncertain world what people are looking for is certainty, relationships, trusted relationships, Australia and Canada are just such partners," he said. Albanese will also hold talks with the EU on a proposed defence pact, and seek progress on EU free trade talks. An annual poll by the Lowy Institute think-tank released on Monday showed falling public sentiment in Australia towards the United States, with 36 per cent of people surveyed saying they trust the United States to act responsibly, a 20-point drop since last year. The poll showed two-thirds of respondents supported AUKUS.
